E-Cig UseRESECNCT05869318
Respiratory Effects of E-Cigarettes in Obese Youth
A study testing ECIG own and ECIG Vuse in people with E-Cig Use, run by Ohio State University Comprehensive Cancer Center at 1 site in United States.
Trial summary
To determine vaping behaviors and respiratory function in obese and nonobese youth e-cigarette users. Read more about this study
- Who is it for?
- Ages 21 to 25 years
- Conditions the study is for
- E-Cig Use
- What is being tested?
- ECIG own and ECIG Vuse
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 56 participants
- Where
- 1 siteUnited States
- Study dates
- 4 Apr 2023to 24 Jun 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 25 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- a current e-cigarette user (≥1 vaping bout daily) for at least the past 3 months,
- 21-25 years old,
- willing to abstain from all tobacco and nicotine for at least 12 hours prior to lab sessions,
- willing to complete five lab visits lasting up to 4 hours each,
- able to read and speak English,
- willing to provide informed consent.
Who cannot join
- self-reported diagnosis of lung disease including asthma or cystic fibrosis
- history of cardiac event or distress within the past 3 months
- history of metabolic disease including thyroid disease or diabetes
- history of orthopedic or neuromuscular problems that preclude exercise
- currently pregnant (determined using urine pregnancy test), planning to become pregnant, delivered a child in the past 6 weeks even if not breastfeeding, or currently breastfeeding
- use of other tobacco products >10 days in the past month
Show all 10Show fewer
- current marijuana use >10 times per month
- currently engaging in a vaping cessation attempt
- ) competitive athlete or individual currently engaged in an exercise training program involving 420min or more (moderate intensity aerobic activity) or 210 min or more (vigorous intensity aerobic activity) per week with the goal of participating in a competitive event or marathon, triathlon, etc. Participants who are engaged in usual physical activity (e.g., walking dog, biking to work, etc.) but not engaged in a "structured exercise training program" will not be excluded.
- plans to leave the Columbus or central Ohio region within the next year.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: RESEC: Respiratory Effects of E-Cigarettes in Obese Youth
To determine vaping behaviors and respiratory function in obese and nonobese youth e-cigarette users.
Read the detailed description
The investigators hypothesize that obese youth e-cigarette users will have increased e-cigarette use that will worsen respiratory function. The approach will involve a clinical trial where vaping behaviors (using puff topography) and respiratory function (spirometry, plethysmography, and diffusion capacity) will be assessed while participants vape with their own e-cigarette and, on a separate visit, with the VUSE e-cigarette.
- Conditions
- E-Cig Use
- Being tested
- ECIG own, ECIG Vuse
- Medical subject headings
- Vaping
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ECIG ownOther
Participants will vape using their own ecig device
ECIG VuseOther
Participants will vape a VUSE e-cigarette (GOLD 5%)
| Study group | Role | What they receive |
|---|---|---|
| Vaping | Experimental | All participants will undergo two vaping sessions: one using their own device and one using the study device Receives: Other: ECIG own; Other: ECIG Vuse |
What is being measured
The primary outcome is the main question the study is designed to answer.
Forced expiratory volume in 1 second
Spirometry will be completed before and after a 35 min vaping session
Measured: Change from 0 to 35 minutes
Functional residual capacity
Plethymosgraphy will be completed before and after a 35 min vaping session
Measured: Change from 0 to 35 minutes
Diffusion capacity
DLCO will be completed before and after a 35 min vaping session
Measured: Change from 0 to 35 minutes
Airway resistance
Plethymosgraphy to measure airway resistance (Raw) will be completed before and after a 35 min vaping session
Measured: Change from 0 to 35 minutes
Puff count
E-cig puff topography data collection for abuse liability
Measured: 35 minutes
Average Puff duration
E-cig puff topography data collection for abuse liability
Measured: 35 minutes
Average Puff volume
E-cig puff topography data collection for abuse liability
Measured: 35 minutes
Secondary outcomes (3)
Tiffany-Drobes Questionnaire of Smoking Urges
Assess E-cig craving/suppression of craving
Measured: Change from 0 to 35 minutes
Respiratory health questionnaire
Assess respiratory symptoms
Measured: Change from 0 to 35 minutes
Exhaled carbon monoxide
Assess carbon monoxide in exhaled air
Measured: Change from 0 to 35 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 May 2023
- Study start4 Apr 2023
- Primary completion21 May 2024
- Study completion24 Jun 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for E-Cig UseStudies of the same condition, open and under way.
- More trials run by Ohio State University Comprehensive Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 56 participants (actual)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dharini Bhammar, Ohio State University Comprehensive Cancer Center
- Investigators
- Dharini M Bhammar, PhD, Principal investigator, Ohio State University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05869318
- Sponsor's protocol ID
- OSU-22219
- Other IDs
- NCI-2023-04458
- Acronym
- RESEC
- Status last verified
- Sep 2026
- First submitted
- 11 May 2023
- Last updated
- 9 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- RESEC: Respiratory Effects of E-Cigarettes in Obese Youth
- ClinicalTrials.gov ID
- NCT05869318
- Acronym / sponsor ID
- RESEC / OSU-22219
- Conditions
- E-Cig Use
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 56 participants (actual)
- Lead sponsor
- Ohio State University Comprehensive Cancer CenterUniversity, hospital or other
- Study start
- 4 Apr 2023 (actual)
- Primary completion
- 21 May 2024 (actual)
- Study completion
- 24 Jun 2025 (actual)
- First posted
- 22 May 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To determine vaping behaviors and respiratory function in obese and nonobese youth e-cigarette users.
Detailed description
The investigators hypothesize that obese youth e-cigarette users will have increased e-cigarette use that will worsen respiratory function. The approach will involve a clinical trial where vaping behaviors (using puff topography) and respiratory function (spirometry, plethysmography, and diffusion capacity) will be assessed while participants vape with their own e-cigarette and, on a separate visit, with the VUSE e-cigarette.
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Vaping | Experimental | Other: ECIG own, Other: ECIG VuseAll participants will undergo two vaping sessions: one using their own device and one using the study device |
Who may qualify
- Ages
- 21 to 25 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- a current e-cigarette user (≥1 vaping bout daily) for at least the past 3 months,
- 21-25 years old,
- willing to abstain from all tobacco and nicotine for at least 12 hours prior to lab sessions,
- willing to complete five lab visits lasting up to 4 hours each,
- able to read and speak English,
Key exclusion criteria (10 listed)
- self-reported diagnosis of lung disease including asthma or cystic fibrosis
- history of cardiac event or distress within the past 3 months
- history of metabolic disease including thyroid disease or diabetes
- history of orthopedic or neuromuscular problems that preclude exercise
- currently pregnant (determined using urine pregnancy test), planning to become pregnant, delivered a child in the past 6 weeks even if not breastfeeding, or currently breastfeeding
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ECIG ownParticipants will vape using their own ecig device | Other | Vaping |
| ECIG VuseParticipants will vape a VUSE e-cigarette (GOLD 5%) | Other | Vaping |
Primary outcome
Forced expiratory volume in 1 second
Time frame: Change from 0 to 35 minutes
Spirometry will be completed before and after a 35 min vaping session
Functional residual capacity
Time frame: Change from 0 to 35 minutes
Plethymosgraphy will be completed before and after a 35 min vaping session
Diffusion capacity
Time frame: Change from 0 to 35 minutes
DLCO will be completed before and after a 35 min vaping session
Airway resistance
Time frame: Change from 0 to 35 minutes
Plethymosgraphy to measure airway resistance (Raw) will be completed before and after a 35 min vaping session
Puff count
Time frame: 35 minutes
E-cig puff topography data collection for abuse liability
Average Puff duration
Time frame: 35 minutes
E-cig puff topography data collection for abuse liability
Average Puff volume
Time frame: 35 minutes
E-cig puff topography data collection for abuse liability
3 secondary outcomes
Tiffany-Drobes Questionnaire of Smoking Urges
Time frame: Change from 0 to 35 minutes
Respiratory health questionnaire
Time frame: Change from 0 to 35 minutes
Exhaled carbon monoxide
Time frame: Change from 0 to 35 minutes
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for E-Cig Use
Enrolling by invitation
Clinical Alternatives for Reducing Harm Using E-cigarettes
Smoking, E-Cig Use
Active, not recruiting
BREATHE Free Curriculum
Smoking Cessation; Tobacco Dependence, E-Cig Use
RecruitingObservational study
Carcinogen and Toxicant Exposure Among Young Adults Who Co-Use Cigarettes, E-cigarettes and Cannabis (Co-Tox Study)
Cigarette Smoking-Related Carcinoma, E-Cig Use
Recruiting
The Role of Flavor in the Substitutability of E-cigarettes for Combustible Cigarettes Among Persistent Smokers
Smoking, Tobacco Use
Not yet recruiting
A Hybrid Program to Prevent Substance Use Risk Among Upper Elementary School Students Using a Positive Youth Development Approach
Vaping, E Cig Use
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Dharini M Bhammar, PhD principal investigator
Ohio State University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing ECIG own and ECIG Vuse in people with E-Cig Use, run by Ohio State University Comprehensive Cancer Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Forced expiratory volume in 1 second (time frame: Change from 0 to 35 minutes). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Sep 2026; AzTrials last refreshed its copy on 7 Nov 2026.